Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805129 | 0.87 | HTR2C (0.45) | SLC6A9L3MBTL1HTR2CSLC6A4TP53 | |
| SCHEMBL3703976 | 0.84 | NOTUM (0.33) | SLC6A9 | |
| SCHEMBL4130901 | 0.83 | TP53 (0.34) | SLC6A9L3MBTL1KMT2ACA2CA4 | |
| SCHEMBL16333316 | 0.81 | KMT2A (0.36) | SLC6A9L3MBTL1KMT2AHTTMEN1 | |
| SCHEMBL3707175 | 0.80 | SLC6A9 (0.33) | SLC6A9L3MBTL1CA2CA4HTT | |
| SCHEMBL4120953 | 0.79 | MAPT (0.34) | SLC6A9L3MBTL1HTR2CSLC6A4HTT | |
| SCHEMBL3702686 | 0.78 | HTR6 (0.40) | HTR2C | |
| SCHEMBL4120305 | 0.78 | MDM2 (0.36) | KMT2AHTR2CSLC6A4HTT | |
| SCHEMBL4119113 | 0.78 | ALDH1A1 (0.33) | HTR2CSLC6A4TP53MAPT | |
| SCHEMBL4131517 | 0.78 | GPBAR1 (0.33) | L3MBTL1KMT2AHTR2CSLC6A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC6A9 2476/4885L3MBTL1 4714/4885KMT2A 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.